Abstract
Background Global tuberculosis (TB) drug resistance (DR) surveillance is largely focused on the drug rifampicin. We leveraged public and surveillance M. tuberculosis (Mtb) whole genome sequencing (WGS) data, to generate more comprehensive country-level resistance prevalence estimates (antibiograms) using in silico resistance prediction.
Methods We curated and quality-controlled Mtb WGS data. We used a validated random forest model to predict phenotypic resistance to twelve drugs and bias-corrected for model performance, outbreak sampling, and resistance oversampling. We validated our estimates using a national DR survey conducted in South Africa.
Results Mtb isolates from 29 countries (n=19,149) met sequence quality criteria. Marginal genotypic resistance estimates overlapped with the South African DR survey for all drugs except isoniazid and second-line injectables that were underestimated (n=3,134); among multi-drug resistant (MDR) TB, estimates overlapped for pyrazinamide and the fluoroquinolones. Globally, mono-resistance to isoniazid was estimated at 10.9% (95% CI: 10.2-11.7%, n = 14,012. Mono-levofloxacin resistance rates were highest in South Asia (Pakistan 3.4% [0.1-11%], n=111 and India 2.8% [0.08-9.4%], n=114). Rates of resistance discordance between isoniazid and ethionamide were high with 74.4% (IQR: 64.5-79.7%) of isoniazid resistant isolates predicted to be ethionamide susceptible. The global susceptibility rate to pyrazinamide and levofloxacin among MDR was 15.1% (95% CI: 10.2-19.9%, n=3,964).
Conclusions This is the first attempt at global Mtb antibiogram estimation. DR prevalence in Mtb can be reliably estimated using public WGS and phenotypic resistance prediction for key antibiotics. Our results raise concerns about the empiric use of short-course fluoroquinolone regimens for drug susceptible TB in South Asia and suggest that ethionamide is an under-utilized drug in MDR treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by National Institutes of Health (R01 AI55765) and the Harvard Global Health Institute Burke Fellowship (MRF). AD was supported by the Boston Childrens Hospital Office of Faculty Development (the Basic and Translational Executive Committee, the Clinical and Translational Research Executive Committee Faculty Career Development Fellowship) and the Bushrod H Campbell and Adah F Hall Charity Fund (Charles A King Trust Postdoctoral Fellowship). RVJ was supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE1745303. MIG was supported by the German Research Foundation (GR5643/1-1). The funders had no role in study design, data collection and interpretation or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Public data used, IRB approval not needed
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All genomes used in the manuscript were sourced from the public database Sequence Read Archive (SRA). All code is available at https://github.com/farhat-lab/tb_antibiogram and data is shown at https://gentb.hms.harvard.edu/maps/antibiogram/.
